BioSpace News Archive

Catalyst Biosciences, Inc. announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock.

Synlogic announced that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will participate in the following upcoming investor conferences

ReNeuron Group plc, a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced fourth quarter 2019 and full year 2019 financial results.

CooperCompanies, will participate in the Oppenheimer 30th Annual Healthcare Conference in New York City, NY, on March 17, 2020.

AVROBIO, Inc., a leading clinical-stage gene therapy company, announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock.

VolitionRx Limited announced it will host a conference call on Friday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2019.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40th Annual Health Care Conference.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®,